MGManuel Emiliano Quiroga Garza

Manuel Emiliano Quiroga Garza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manuel Emiliano Quiroga Garza has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Radiation retinopathy: a review

    by Ali Khodor, Maria F. Colorado-Zavala, Raul E. Ruiz-Lozano, Manuel E. Quiroga-Garza, Eugenia M. Ramos-Dávila, Pachely Mendivil-Aguayo, Symon Ma, Amr Almobayed, Chima Orameh, Shilpa J. Desai

  • Clinical Features and Treatment Outcomes of Patients with Tubulointerstitial Nephritis and Uveitis Syndrome: A Case Series

    by Raul E. Ruiz-Lozano, Paulina Liberman, Aaron T. Zhao, Symon Ma, Matthew B. Urban, Ali Khodor, Manuel E. Quiroga-Garza, Eugenia M. Ramos-Dávila, Hazem M. Mousa, Shima Dehghani, et al.

    Describe the demographic and clinical characteristics, treatment outcomes, and ocular complications in patients with tubulointerstitial nephritis and uveitis (TINU) syndrome. Retrospective study of TINU patients seen at the Foster Center for Ocular Immunology (Duke University) and Wilmer Eye Institute (Johns Hopkins School of Medicine) between January 2014-December 2023. Patients were diagnosed using the 2021 SUN Working Group criteria. 27 TINU patients, 16 (59%) males, aged 20.4 ± 15.8 (range: 7-71) years were included. The mean follow-up time was 24.3 ± 16.5 (range: 7-75) months. All tested patients had an elevated urinary β2-microglobulin. Ten (37%) patients had positive renal biopsy. Thirteen (48%) patients presented with isolated anterior uveitis, and 14 (52%) had additional intermediate/posterior segment findings in at least one eye. At baseline, all patients were managed with topical corticosteroids (TCS), with 6 (27%) patients requiring oral prednisone (PRD) and 17 (63%) steroid-sparing immunosuppressive therapy (SS-IMT). Inflammatory control was achieved in 26 (96%) patients with TCS only (n = 4), TCS+PRD (n = 5), TCS+SS-IMT (n = 6), and TCS+PRD+SS-IMT (n = 11). Thirteen of 26 patients (50%) developed disease relapse at a mean time of 8.9 ± 18.9 (range: 1-71) months. One patient was lost to follow-up. Eighteen (67%) patients developed TINU-associated ocular complications. Five eyes from 4 patients had a median decrease in visual acuity of 2 Snellen lines (range: 1-4) during follow-up. The demographic and clinical presentation of TINU is heterogeneous. Intermediate and posterior segment manifestations are common. Treatment with topical and systemic corticosteroids only may be insufficient to prevent disease relapse, with most patients requiring long-term immunosuppressive therapy.

  • Open Access

    Correction: Functional and Anatomical Outcomes of Faricimab in Previously Treated Wet Age-Related Macular Degeneration: Systematic Review and Pooled Analysis

    by Ali Khodor, Jonathan T. Caranfa, Tavish Nanda, Raul E. Ruiz-Lozano, Manuel E. Quiroga-Garza, Stephanie Choi, Ali Chehab, Eugenia M. Ramos-Dávila, Jeffrey S. Heier, Chirag P. Shah, et al.

  • Open Access

    Functional and Anatomical Outcomes of Faricimab in Previously Treated Wet Age-Related Macular Degeneration: Systematic Review and Pooled Analysis

    by Ali Khodor, Jonathan T. Caranfa, Tavish Nanda, Raul E. Ruiz-Lozano, Manuel E. Quiroga-Garza, Stephanie Choi, Ali Chehab, Eugenia M. Ramos-Dávila, Jeffery S. Heier, Chirag P. Shah, et al.

    Introduction To evaluate the outcomes of intravitreal faricimab (IVF; Vabysmo®) in previously treated patients with wet age-related macular degeneration (wAMD), focusing on best available visual acuity (BAVA), central subfield thickness (CST), injection interval, complications, fluid resolution, and reversion rates to prior therapies. Methods The PubMed, Embase, and Google Scholar databases were searched for studies reporting outcomes of treatments for previously treated cases of wAMD. Mean differences (MD) with 95% confidence intervals (CI) were used to compute the effect size of the change in outcomes. Results A total of 29 studies with 2070 patients (1003 women, mean age 78.9 years) and 2128 eyes were included. BAVA and CST were reported in 28 studies, fluid status in 21, injection interval in 14, and reversion rates in 6. Pooled analysis showed significant but modest improvement in BAVA when IVF was given for > 6 months (MD = −0.026 LogMAR, p < 0.05) but not at earlier follow-ups. A similar trend was noted with injection interval extension when IVF was given beyond 6 months (MD = +2.1 weeks, p < 0.05). CST reduction was observed at all time points (overall MD = −37.7 μm, p < 0.05). Complication rates were reported in nine studies, with an overall rate of 1.2%, including retinal pigment epithelium tear, intraocular inflammation, endophthalmitis, and subretinal hemorrhage. Reversion to prior or other anti-vascular endothelial growth factor (anti-VEGF) therapy was reported in six studies, occurring in 23% of eyes. Conclusions We reported the outcomes of utilizing IVF in previously treated cases of wAMD. IVF showed a significant improvement in CST at all time points and in the extension of injection interval. Visual outcomes remained unchanged when followed for less than 6 months but improved significantly but modestly when followed for more than 6 months. Switching to intravitreal faricimab may be a useful treatment option for previously treated patients with wAMD, with a goal of reducing treatment burden and improving treatment efficacy.


  • Prevalence and morphometric characteristics of primary cornea guttata in a Hispanic population

    by Gustavo Ortiz-Morales, Andres Bustamante-Arias, Manuel Emiliano Quiroga-Garza, Enrique Graue-Hernandez, Alejandro Rodriguez-Garcia, Jorge E. Valdez-García

    Purpose To describe the prevalence and the corneal endothelium´s morphology in Hispanic patients with primary corneal guttata (PCG). Methods Retrospective comparative study of PCG and healthy individuals. Results 122 (17.38%) PCG out of 702 eyes from 356 healthy patients with no surgeries nor a familiar history of Fuchs´ dystrophy were studied. The mean age of PCG patients was 68.12 ± 10.59 years (45–88 years). While the mean cell density (MCD) in PCG group was 1893.61 ± 597.01 cells/mm2, the cell area was 590.67 ± 257.57 µm2, and the central corneal thickness (CCT) was 527.67 ± 46.56 µm, in healthy control group, the MCD was 2341.89 ± 488.07 cells/mm2 (p < 0.0001), the mean cell area was 428.99 ± 166.62 µm2(p < 0.0001), and the mean CCT was 521.24 ± 39.87 µm (p = 0.74). 64.75% of patients had polymegethism and 81.15% had pleomorphism. 83.88% of patients had less than 25% of the total area affected. Females predominate the PCG group (65.57%), and they exhibit significantly higher rates of polymegethism (59.49%) and pleomorphism (63.64%). Conclusion A high proportion of PCG was observed in this Hispanic population. These patients show a lower-than-average MCD compared to a healthy population. A high rate of polymegethism and pleomorphism was observed, particularly in females, where PCG was more frequent.


  • Open Access

    Validation of the Zarit Burden Interview in Informal Caregivers of Patients with Severe Visual Impairment and Blindness

    by Raul E. Ruiz-Lozano, Monica I. Herrera-Rodriguez, Jazmin A. Mendoza-Pallares, Natalia Reyes-Godinez, Veronica E. Tamez-Tamez, Eugenia M. Ramos-Dávila, Luis G. Villagomez-Valdez, Lucas A. Garza-Garza, Manuel E. Quiroga-Garza, Ali Khodor, et al.

    Introduction The needs of family caregivers providing care to relatives with visual impairment are often dismissed, leading to caregiver burden. The Zarit Burden Interview (ZBI) can measure the caregiver burden of caring for a family member with vision impairment. The purpose of this study is to validate the ZBI in Mexican family caregivers of patients with visual impairment. Methods The ZBI was applied to 137 family caregivers of patients with visual acuity ≤ 20/200 in the best eye for ≥ 6 months. The ZBI’s reliability was determined using Cronbach’s α and the factor structure using exploratory factor analysis (EFA, principal axis factoring with promax rotation). Items with loadings < 0.400 were eliminated. Retained factors were determined using the scree test and Horn’s parallel analysis (95% CI). Associations between burden factors and other variables were evaluated with descriptive and inferential statistics. Results Mean ZBI score was 26.2 ± 13.1, and internal consistency was high (α = 0.871). EFA yielded four factors: (1) embarrassment and frustration, (2) self-efficacy expectations, (3) interference in personal relationships, and (4) personal strain. The α values ranged from 0.649 to 0.812. Spousal caregivers had significantly higher scores (factors 1, 2, and 4), whereas adult children had less scores (factor 3). There was a significant positive correlation between hours of daily caregiving and factors 2 (r = 0.350) and 3 (r = 0.388). A worse degree of visual impairment was associated with higher mean factor scores in all factors. Conclusions The ZBI is a valid instrument to detect burden in Mexican caregivers of patients with visual impairment. We identified a four-factor structure that improved our understanding of the ZBI’s underlying constructs. Interventions targeting specific types of burden are warranted.


  • Open Access

    Adalimumab to treat noninfectious pediatric chronic anterior uveitis: a case series

    by Raul E. Ruiz-Lozano, Hazem M. Mousa, Matias Soifer, Nadim S. Azar, Manuel E. Quiroga-Garza, Daliya Dzhaber, Sofia Murillo, Ailin Song, C. Egla Rabinovich, Victor L. Perez

    Purpose: Evaluate the response to adalimumab (ADA) in pediatric chronic anterior uveitis (pCAU). Methods: Retrospective chart review of pCAU patients treated with ADA. Outcomes evaluated included the proportion of patients achieving zero ocular inflammation and discontinuation of topical corticosteroids, visual outcomes, and incidence of uveitis recurrences after ≥ 12 months of prescribing ADA. Incidence and risk factors for developing anti-adalimumab antibodies (AAAs) were also evaluated. Results: Of 27 children aged 11 years, 16 (59%) were Caucasian and 6 (22%) African Americans. Thirteen (48%) patients had idiopathic pCAU, 12 (44%) had juvenile idiopathic arthritis (JIA) related pCAU, and 2 (7%) had tubulointerstitial nephritis and uveitis syndrome. At baseline, African American children had worse visual acuity (p = 0.026). At 1 year, 21 (78%) children achieved zero ocular inflammation (remission). Risk factors associated with non-remission were being African American (20% vs. 94%, p = 0.003) and experiencing ≥ 1 episode of uveitis recurrence (100% vs. 0%, p < 0.001). Six episodes of uveitis recurrence were documented in five children, four of whom were African American. Topical corticosteroids were discontinued in 83% of children, and visual acuity remained stable for 1 year. Twelve children were tested for AAAs due to arthritis or uveitis flare-ups, with five (42%) being positive. No significant factors were associated with the development of AAAs. Conclusions: We found that ADA is effective in controlling inflammation, reducing the need for topical corticosteroids, and maintaining visual acuity in pCAU. There appears to be racial differences in African American children who had worse baseline disease and poorer outcomes. Studies are necessary to understand better and address these disparities.


  • Deep-learning based analysis of in-vivo confocal microscopy images of the subbasal corneal nerve plexus’ inferior whorl in patients with neuropathic corneal pain and dry eye disease

    by Raul E. Ruiz-Lozano, Matias Soifer, Zane Z. Zemborain, Nadim S. Azar, Manuel E. Quiroga-Garza, Sofia Murillo, Symon Ma, Seitaro Komai, Anupama Horne, Ali Khodor, et al.


  • Clinical Course and Outcomes of Autoimmune Versus Non-Autoimmune Surgically Induced Scleral Necrosis: A Multicentric Comparative Study

    by Raul E. Ruiz-Lozano, Eugenia M. Ramos-Dávila, Maria F. Colorado-Zavala, Manuel E. Quiroga-Garza, Nadim S. Azar, Hazem M. Mousa, Victor L. Perez, Maite Sainz-De-La-Maza, C. Stephen Foster, Alejandro Rodriguez-Garcia

    To analyze the clinical course and outcomes of autoimmune vs. non-autoimmune surgically induced scleral necrosis (SISN). Multicentric, retrospective, comparative cohort study. Eighty-two eyes of 70 patients with SISN were classified according to pathogenic mechanism into autoimmune vs. non-autoimmune. Main outcome measures included necrosis onset, type of surgery, associated systemic disease, visual acuity, and treatment were analysed in patients followed for ≥ 6 months. Forty-six (65.7%) patients were women, and the median age was 66 (range: 24-90) years. Most patients (82.9%) had unilateral disease. The median time between surgery and SISN onset was 58 (1-480) months. Thirty-one (37.8%) eyes were classified as autoimmune, and 51 (62.2%) as non-autoimmune SISN. Autoimmune SISN was associated with a shorter time between the surgical procedure and SISN onset than non-autoimmune cases (median of 26 vs. 60 months, p = 0.024). Also, autoimmune SISN was associated with cataract extraction (93.5% vs. 25.5%, p < 0.001), severe scleral inflammation (58.1% vs. 17.6%, p < 0.001), and higher incidence of ocular complications (67.7% vs. 33.3%, p = 0.002) than non-autoimmune cases. Remission was achieved with medical management alone in 44 (86.3%) eyes from the non-autoimmune and in 27 (87.1%) from the autoimmune group (p = 0.916). Surgical management was required in 11 (13.4%) eyes, including two requiring enucleations due to scleral perforation and phthisis bulbi. Eyes with autoimmune SISN had a higher rate of cataract surgery, severe scleral inflammation, and ocular complications. Early SISN diagnosis and appropriate management, based on clinical features and pathogenic mechanisms, are critical to avoid sight-threatening complications.


  • Lessons Learned From Ocular Graft versus Host Disease: An Ocular Surface Inflammatory Disease of Known Time of Onset

    by Manuel E. Quiroga-Garza, Raul E. Ruiz-Lozano, Luis A. Rodriguez-Gutierrez, Ali Khodor, Symon Ma, Seitaro Komai, Karim Mohamed-Noriega, Victor L. Perez

    The ocular surface inflammatory disorders (OSIDs) comprise a group of conditions characterized by persistent inflammation of the ocular surface and adnexal tissues. Systemic autoimmune diseases and hypersensitivity reactions cause them, and, if left untreated, can result in severe inflammatory dry eye, corneal damage, and vision loss. Ocular graft-versus-host disease (oGVHD) forms part of the ocular surface inflammatory disease umbrella. It is a condition occurring after allogeneic hematopoietic stem cell or bone marrow transplantation, usually in chronic graft-versus-host disease. oGVHD can virtually affect any ocular adnexal tissue, especially the meibomian glands, and cause persistent inflammation, tissue fibrosis, and subsequent chronic, severe dry eye disease. Among the OSIDs, oGVHD has the particularity that it has a “time zero,” meaning we know when the disease started. As such, preclinical models have leveraged this to investigate the molecular mechanisms involved in the damage oGVHD causes to the ocular surface. In oGVHD, establishing a “time zero” allows for predicting the clinical course and establishing adequate treatment. This is also possible because the inflammatory infiltration occurs in ocular surface tissues, which are readily accessible. Using oGVHD, we might be able to understand the immune response mechanisms in other OSIDs better (i.e., Sjögren syndrome, Stevens-Johnson syndrome, among others). This review presents an up-to-date overview of the pathogenesis, clinical presentation, and treatment of oGVHD. In addition, we will discuss the value of the “time zero” concept in the study of oGVHD.